What To Know About Citigroup's Upgrade of Mersana Therapeutics
Portfolio Pulse from Benzinga Insights
Citigroup has upgraded Mersana Therapeutics (NASDAQ:MRSN) to a Buy rating with a new price target of $5.00, up from the previous target of $1.00. Mersana's shares have risen 5.26% to $2.00 in the last 24 hours. The new price target suggests a potential upside of 150.0% from the current share price. Mersana is a clinical-stage biopharmaceutical company focused on developing targeted drugs with its proprietary ADC platforms.
December 04, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup upgraded Mersana Therapeutics to Buy and increased the price target from $1.00 to $5.00, indicating a significant potential upside.
The upgrade by Citigroup is a strong positive signal for investors, suggesting increased confidence in Mersana's prospects. The substantial raise in the price target could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100